| Literature DB >> 23726034 |
Pascal Furet1, Vito Guagnano, Robin A Fairhurst, Patricia Imbach-Weese, Ian Bruce, Mark Knapp, Christine Fritsch, Francesca Blasco, Joachim Blanz, Reiner Aichholz, Jacques Hamon, Doriano Fabbro, Giorgio Caravatti.
Abstract
Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research. On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compounds in inhibiting PI3Kα, a medicinal chemistry program has led to the discovery of the clinical candidate NVP-BYL719.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23726034 DOI： 10.1016/j.bmcl.2013.05.007
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823